GSK (GSK) Competitors

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 34.52% compared to GSK's net margin of 9.89%. Novo Nordisk A/S's return on equity of 80.94% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.52%	80.94%	24.23%
GSK	9.89%	48.82%	11.15%

Which has higher earnings and valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$303.14B	1.02	$14.64B	$3.38	20.43
GSK	$31.53B	2.48	$3.29B	$1.94	19.72

Which has more volatility and risk, NVO or GSK?

Novo Nordisk A/S has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Do analysts rate NVO or GSK?

Novo Nordisk A/S presently has a consensus target price of $112.00, suggesting a potential upside of 62.20%. GSK has a consensus target price of $37.38, suggesting a potential downside of 2.31%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.10

Do institutionals and insiders believe in NVO or GSK?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is NVO or GSK a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. GSK pays an annual dividend of $1.68 per share and has a dividend yield of 4.4%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. GSK pays out 86.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Does the media refer more to NVO or GSK?

In the previous week, Novo Nordisk A/S had 13 more articles in the media than GSK. MarketBeat recorded 30 mentions for Novo Nordisk A/S and 17 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 1.31 beat GSK's score of 0.87 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats GSK on 14 of the 18 factors compared between the two stocks.